JBTM Latest Report

DataVisMonday, Mar 3, 2025 1:53 am ET

1min read

Key Financial Data

1. JBT Marel's operating revenue in 2024 reached RMB467.6 million, up 5.83% from RMB444.6 million in 2023. This growth reflects the company's improvement in sales capabilities, possibly related to increased market demand and expanded market share.

2. Sales costs rose from RMB283.8 million to RMB288.2 million, although costs increased, gross profit rose from RMB160.8 million to RMB179.4 million, indicating the company's efficiency in cost control.

3. In 2024, jbt marel launched several new products, including Toxoplasma gondii antibody test kits and cytomegalovirus antibody test kits, which are expected to further drive revenue growth.

Peer Comparison

1. Industry-wide analysis: In 2024, the overall industry's operating revenue generally increased, especially in the field of technology and automation equipment, with industry companies generally benefiting from the rise in market demand and technological innovation, with an overall growth rate of about 4% to 7%.

2. Peer evaluation analysis: JBT Marel's 5.83% growth rate is higher than the industry average, indicating that the company performed well in the market competition, possibly due to its advantages in product innovation and customer service.

Summary

JBT Marel showed stable revenue growth in 2024, reflecting the company's improvement in market sales capabilities and cost control. Compared with peers, its growth rate is at the industry's leading level, indicating that it can maintain its advantages in fierce competition.

Opportunities

1. The launch of new products will expand market appeal and help further boost operating revenue.

2. Through continuous product research and innovation, JBT Marel can enhance its competitiveness in the international in vitro diagnostic market.

3. With the overall recovery of the industry, future market demand may increase, providing more sales opportunities for the company.

Risks

1. Industry clients' budget cuts may lead to a slowdown in procurement rhythm, affecting the signing of orders.

2. Intense external competition may put pressure on the company's operating revenue in the short term.

3. Changes in the economic environment may affect the company's profits and revenue, and it needs to continuously monitor market dynamics to adjust strategies.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.